Fresh news on health and wellness in Tajikistan

Provided by AGP

Tajikistan Health News: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tajikistan Health News.

Press releases published on May 14, 2026

EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
Aveanna Healthcare Holdings Announces First Quarter Financial Results and Revised 2026 Guidance
BrewDog Shakes Up RTD Shelves Across the UK with New Nostalgia-Led Wonderland Cocktails
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
Pelthos Therapeutics Announces First Quarter 2026 Financial Results
Hyperion DeFi Reports 1Q 2026 Financial Results with Record Net Income and Raises Guidance for Full Year 2026
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update
Cyclarity Unveils First-Ever Clinical Data Demonstrating Excretion of Oxidized Cholesterol, at American Heart Association Vascular Discovery Scientific Sessions
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
XORTX Announces US$5 Million Public Offering
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

Share us

on your social networks:

Sign up for:

Tajikistan Health News

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.